Walvax Biotechnology (300142) Stock Price, Fundamentals & Analysis

What 300142 does

Walvax Biotechnology (300142) is a stock listed on the Shenzhen Stock Exchange in the Healthcare sector, specifically within the Drug Manufacturers – Specialty & Generic industry. The company researches, manufactures, and distributes vaccines in China and internationally, with a portfolio that includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. It is headquartered in Kunming, China, and has 1,981 employees.

Key numbers explained

• 13.58 CNY is the current price per share.
• The trailing P/E ratio of 113.2 shows how much investors pay per unit of recent earnings; a high number can signal growth expectations or a stretched valuation.
• The forward P/E ratio of 30.2 uses expected future earnings and is typically lower than the trailing figure when earnings are forecast to grow.
• Earnings per share for the trailing 12 months is 0.12 CNY, a measure of profitability per share.
• The dividend yield of 1.14% indicates the annual cash return relative to the share price; the ex-dividend date is Jun 24, 2026.
• A beta of 0.62 suggests the stock has historically moved less than the overall market.
• The 52-week range of 10.88 – 16.97 shows the lowest and highest traded prices over the past year.
• Revenue, trailing 12 months, is 2.1 mld. CNY, with a year-over-year growth of -43.6%.
• Profit margin is 9%, while operating margin is -7.3%, and return on equity is 2%.
• The debt-to-equity ratio of 17.7% indicates a modest level of debt relative to shareholders’ equity.
• Price-to-book of 3.11 compares the market price to the company’s book value per share.

What to watch

Investors tracking Walvax Biotechnology may monitor vaccine pipeline updates, regulatory approvals, and pricing dynamics in the specialty vaccine space. Revenue trends and margin performance are also relevant, given the -43.6% year-over-year revenue decline and the negative operating margin of -7.3%. Because the stock trades on the Shenzhen Stock Exchange, broader Chinese healthcare policy and market sentiment can influence its movements. For context, peers such as Zhejiang NHU (002001), Mindray (300760), Pharmaron Beijing (300759), Huadong Medicine (000963), Aier Eye Hospital (300015), Shijiazhuang Yiling Pharmaceutical (002603), and Chongqing Zhifei Biological Products (300122) operate in related areas of the Shenzhen Stock Exchange stocks universe.